ERBB2 and breast cancer: Here, we describe for the first time the therapeutic activity of a trastuzumab-based, HER2-targeting ADC incorporating a derivative of a novel anthracycline payload PNU-159682 (short T-PNU) in an orthotopic, syngeneic murine breast cancer model.